Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein A. Tawbi(The University of Texas MD Anderson Cancer Center), Melissa Burgess(University of Pittsburgh), Vanessa Bolejack(Cancer Research And Biostatistics), Brian A. Van Tine(Washington University in St. Louis), Scott M. Schuetze(University of Michigan–Ann Arbor), James Hu(University of Southern California), Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center), Steven Attia(WinnMed), Richard F. Riedel(Duke University), Dennis A. Priebat(MedStar Washington Hospital Center), Sujana Movva(Fox Chase Cancer Center), Lara E. Davis(Oregon Health & Science University), Scott H. Okuno(Mayo Clinic in Florida), Damon R. Reed(Moffitt Cancer Center), John Crowley(Cancer Research And Biostatistics), Lisa H. Butterfield(University of Pittsburgh), Ruth Salazar(The University of Texas MD Anderson Cancer Center), Jaime Rodriguez‐Canales(The University of Texas MD Anderson Cancer Center), Alexander J. Lazar(The University of Texas MD Anderson Cancer Center), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center), Laurence H. Baker(University of Michigan–Ann Arbor), Robert G. Maki(Hofstra University), Denise K. Reinke(Sarcoma Alliance for Research through Collaboration), Shreyaskumar Patel(The University of Texas MD Anderson Cancer Center)
Cited by 1,408Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis